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Background:  Glutamate has been claimed to protect the heart from ischemia and to facilitate metabolic and hemodynamic recovery after 
ischemia. The GLUTAMICS-trial investigated if intravenous glutamate infusion given in association with surgery for acute coronary syndrome can 
reduce mortality and prevent or mitigate myocardial injury and postoperative heart failure.
Methods:  In this investigator-initiated prospective, double-blind study 861 patients undergoing surgery for acute coronary syndrome in three 
Swedish Hospitals were randomly assigned to intravenous infusion of glutamate (n=428) or saline (n=433) perioperatively. The primary endpoint 
was a composite of postoperative mortality (30 days), perioperative myocardial infarction and left ventricular heart failure on weaning from 
cardiopulmonary bypass.
Results:  Thirty-day mortality was 0.9 % in the glutamate group and 1.2% in the control group. Cardiac mortality was 0.2% in the glutamate group 
and 0.9% the control group. The incidence of the composite primary end point was 7.2% in the glutamate group and 5.8% in the control group. 
None of these differences were statistically significant.
Regarding secondary end points significantly fewer patients in the glutamate group were hemodynamically unstable at completion of surgery (0.3% 
v 1.8%; p=0.035) or in need of intra-aortic balloon pump on arrival to the intensive care unit (0.0% v 1.2%; p=0.026). In patients with severe 
unstable angina (CCS class IV; n=475) the incidence of severe circulatory failure according to prespecified criteria was significantly lower in the 
glutamate group (2.6% v 6.6%; p=0.036).
Conclusions:  The primary endpoint did not differ significantly between the groups. Regarding secondary end points there were significant 
differences compatible with a beneficial effect of glutamate on myocardial recovery. (ClinicalTrials.gov Identifier: NCT00489827)
